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Abstract
Context: For more precise, personalized care in prostate cancer (PC), a new classification
based on molecular features relevant for prognostication and treatment stratification is
needed. Genomic aberrations in the DNA damage repair pathway are common in PC,
particularly in late-stage disease, and may be relevant for treatment stratification.
Objective: To review current knowledge on the prevalence and clinical signiﬁcance of
aberrations in DNA repair genes in PC, particularly in metastatic disease.
Evidence acquisition: A literature search up to July 2016 was conducted, including
clinical trials and preclinical basic research studies. Keywords included DNA repair, BRCA,
ATM, CRPC, prostate cancer, PARP, platinum, predictive biomarkers, and hereditary cancer.
Evidence synthesis: We review how the DNA repair pathway is relevant to prostate
carcinogenesis and progression. Data on how this may be relevant to hereditary cancer
and genetic counseling are included, as well as data from clinical trials of PARP inhibitors
and platinum therapeutics in PC.
Conclusions: Relevant studies have identiﬁed genomic defects in DNA repair in PCs in
20–30% of advanced castration-resistant PC cases, a proportion of which are germline
aberrations and heritable. Phase 1/2 clinical trial data, and other supporting clinical data,
support the development of PARP inhibitors and DNA-damaging agents in this molecu-
larly deﬁned subgroup of PC following success in other cancer types. These studies may
be an opportunity to improve patient care with personalized therapeutic strategies.
Patient summary: Key literature on how genomic defects in the DNA damage repair
pathway are relevant for prostate cancer biology and clinical management is reviewed.
Potential implications for future changes in patient care are discussed.
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While therapeutic options for patients with advanced
prostate cancer (PC) have improved over the last decade,
castration-resistant PC (CRPC) remains a lethal disease
[1]. Recently, relevant studies have identified genomic
defects in DNA repair in advanced and primary PC. This has
led to clinical studies that provide a strong rationale for
developing PARP inhibitors and DNA-damaging agents in
this molecularly defined PC subgroup. Following the
successful development of targeted agents for molecularly
defined subpopulations in other cancer types [2,3], there
may be an opportunity to potentially improve patient care
in PC via personalized therapeutic strategies. In this article,
we review the biology and clinical implications of
deleterious inherited or acquired DNA repair pathway
aberrations in PC.
2. Evidence acquisition
A literature search for clinical trials and preclinical
basic research studies up to July 2016 was conducted.
Keywords for the included ‘‘DNA repair’’, ‘‘BRCA’’, ‘‘ATM’’,
‘‘CRPC’’, ‘‘prostate cancer’’, ‘‘PARP’’, ‘‘platinum’’, ‘‘predic-
tive biomarkers’’, and ‘‘hereditary cancer’’.
3. Evidence synthesis
3.1. The molecular landscape of primary and advanced PC
Advances in genomics have permitted the identification of
putative drivers of carcinogenesis and cancer progression.
These genomic data provide for precise molecular tumor
subclassification that extends beyond traditional histologic
descriptions. For optimal utility, molecular clusters should
provide prognostic or predictive information relevant for
patient care [4].Table 1 – Prevalence of DNA repair gene mutations and deletions desc
Study Disease status Samples 
(n) Ho
SU2C-PCF CRPC CRPC metastasis 150 BRCA1 
genomic landscape BRCA2 
[12] ATM 
UM PC genomics CRPC metastasis 50 BRCA1 
[11] BRCA2 
ATM 
UM PC genomics Treatment-naı¨ve tumors 11 BRCA1 
[11] BRCA2 
ATM 
Weill Cornell/Broad Prostatectomy for localized 109 BRCA1 
[6] or locally advanced PC BRCA2 
(somatic only) ATM 
TCGA localized PC Localized PC 333 BRCA1 
[8] BRCA2 
ATM 
MMR = mismatch repair; NER = nucleotide-excision repair; PC = prostate cance
Cancer Foundation; UM = University of Michigan; TCGA = The Cancer Genome At
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primary prostate tumors [5–7]. Recently, The Cancer
Genome Atlas Research Network (TCGA) reported on
whole-exome sequencing of a series of 333 localized PCs
[8]. Seven subgroups were defined on the basis of certain
gene fusions involving the ERG/ETS transcription factor
family (ERG, ETV1/4, and FLI1) or recurrent mutations in
specific genes (SPOP, FOXA1, and IDH1); these subgroups
differ with regard to androgen receptor (AR) signaling
activity, DNA methylation, and microRNA expression.
In the TCGA study, in which Gleason 8 tumors
represented 26% of the cohort, 62/333 (19%) tumors had
deleterious germline or somatic aberrations in genes key to
the DNA damage repair pathway (BRCA2, BRCA1, CDK12,
ATM, FANCD2, RAD51C). Six of these aberrations involved a
BRCA2 K3326* nonsense germline variant, which arguably
does not greatly impact protein function despite a modest
association with risk of cancer [9], and 23 cases had
heterozygous deletions of FANCD2 or RAD51 without
evidence of biallelic inactivation; consequently, the pro-
portion of localized PCs with impaired DNA repair function
is probably less than 19%.
Next-generation sequencing studies of metastatic
tumors identified enrichment of mutations in DNA repair
genes among patients with lethal disease [10,11]. To
provide a systematic analysis of the genomic landscape of
CRPC and its potential relevance for patient care, the Stand
Up To Cancer (SU2C)-Prostate Cancer Foundation (PCF)
International Dream Team pursued whole-exome and
transcriptome sequencing of 150 biopsies from metastatic
CRPC (mCRPC) [12]. Higher prevalence of aberrations in key
DNA repair genes (23%), TP53 (53%), RB1 (21%), the PTEN-
PI3K pathway (49%), and AR (63%) in mCRPC than in
localized disease was confirmed. It is not yet clear if this
enrichment is secondary to a tumor evolution process in
response to therapy exposure, or purely suggests markers of
more aggressive PCs (Table 1).ribed in studies on localized and metastatic prostate cancer
Gene frequency
mologous recombination MMR NER
0.7% CDK12 4.7% MLH1 1.3% ERCC2 1.3%
13.3% CHEK2 3.0% MSH2 3.0% ERCC5 1.3%
7.3% PALB2 2.0% MSH6 2.0%
0% CDK12 6.0% MLH1 2.0% ERCC2 2.0%
12.0% CHEK2 MSH2 2.0% ERCC5 12.0%
6.0% PALB2 0% MSH6 2.0%
0% CDK12 0 MLH1 0 ERCC2 0
1/11 CHEK2 0 MSH2 1/11 ERCC5 0
1/11 PALB2 0 MSH6 1/11
1.8% CDK12 0 MLH1 0 ERCC2 0
0% CHEK2 0 MSH2 0 ERCC5 0
2.8% PALB2 1.8% MSH6 0.9%
1.0% CDK12 2.0% MLH1 0.3% ERCC2 0.6%
3.0%* CHEK2 0% MSH2 0.3% ERCC5 0.3%
4.0% PALB2 0% MSH6 1.5%
r; CRPC = castration-resistant PC; SU2C-PCF = Stand Up To Cancer-Prostate
las.
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identified inactivation of key DNA repair genes in at least
23% of cases, including homologous recombination (HR)–
mediated repair genes (most commonly BRCA2 and ATM)
and mismatch repair (MMR) genes (MLH1, MSH2). Other
DNA repair mechanisms are also likely to be impacted
because of known influences of the AR in nonhomologous
end-joining (NHEJ), and possibly aberrations in nucleotide
excision repair (NER) and base excision repair (BER).
Intrapatient tumor heterogeneity represents a challenge
for genomic stratification of PC in the clinic. Several studies
have comprehensively observed an overall higher degree of
heterogeneity within primary prostate tumors than in
advanced disease [13–15]. This is likely to be related to: (1)
bottlenecks in the metastatic process that limit metastatic
spread and growth; (2) the capacity of metastatic tumor
cells to seed other metastasis and even reseed the primary
tumor; and (3) the selection of resistant clones driven by
treatment exposures. Alterations in DNA repair genes have
been related to increased mutational burden and may
generate increased intrapatient heterogeneity; specific
studies addressing the impact of genomic instability on
treating the diverse subtypes of this common disease are
now needed.
3.2. The DNA damage response pathway: a general overview
At any time, the DNA in human cells is constantly being
damaged. If there is a deficient repair of this damage,
genome stability is compromised, which can contribute to
tumorigenesis. Damage can occur endogenously (due to
spontaneous hydrolysis of bases or reaction of DNA with
naturally occurring reactive oxygen species or alkylating
agents) or can be induced by exogenous agents (eg,
radiation and toxins). To protect their genome integrity,
cells have evolved a complex signaling machinery for
recognizing and repairing damage that includes several
pathways with complementary and partially overlapping
functions. Different forms of DNA damage trigger a response
from different branches of this complex system. The main
workflow is as follows; when genomic insults are detected,
cell-cycle checkpoints are activated to halt the cell cycle and
allow the cellular machinery to repair the DNA damage. If
the repair is successful, the cell can continue its normal
cycle; otherwise, programmed cell death or senescence
programs are triggered. If the DNA repair mechanisms are
dysfunctional, genomic instability, which is one of the
hallmarks of carcinogenesis, ensues.
When damage is limited to one of the DNA strands
(single-strand breaks or base modifications), different
repair mechanisms can be deployed. These include BER,
single-strand break repair (SSBR), NER, and MMR. Each of
these pathways uses the complementary undamaged
strand as a template to ensure fidelity of repair. BER is
mainly activated to repair endogenous oxidative or
alkylated base damage [16]. PARP1 and PARP2 are involved
in detecting single-strand breaks, which are formed either
directly or as intermediates in BER, and help to coordinate
the SSBR response. The NER machinery is responsible forPlease cite this article in press as: Mateo J, et al. DNA Repair in Pros
http://dx.doi.org/10.1016/j.eururo.2016.08.037repairing bulky adducts such as those induced by UV light,
for which the ERCC family of proteins are key mediators. The
MMR pathway corrects mutations formed during DNA
replication and recombination. The MSH and MLH family of
genes are, among others, critical for MMR. The primary
mechanisms involved in DNA double-strand break (DSB)
repair comprise the HR system and NHEJ. HR requires a
sister chromatid as template and is therefore restricted to
the S/G2 phases of the cell cycle. It restores the original DNA
code error-free. Key mediators of this pathway include
BRCA1, BRCA2, PALB2, ATM, ATR, RAD51, MRE11, CHEK2,
and XRCC2/3. In contrast, NHEJ functions by ligating broken
DNA ends without the use of a template and is therefore
functional throughout the cell cycle. The error-prone mode
of NHEJ action leads to errors that are permanent and can
drive genomic instability (Fig. 1). SSBs that are not repaired
before DNA replication takes place will collapse replication
forks, leading to formation of DSBs, which then require HR
for repair and continued replication [17].
3.3. DNA repair defects play a relevant role in carcinogenesis
and PC progression
Prostate carcinogenesis is mediated, as in other cancers, by
the accumulation of genetic and epigenetic aberrations;
these molecular changes can be inherited or be the result of
altered AR transcriptional activity, changes in chromatin
architecture, oncogenic replication, error-prone DNA repair,
or defective cell division. The sum of these processes confers
survival and growth advantage to the transformed cell.
Many of these alterations are induced by factors of the
microenvironment, particularly the immune system. Chron-
ic inflammation with continued oxidative stress contributes
to carcinogenesis of the prostate epithelium by inducing
genomic damage. Deficient DNA repair response and
defective apoptotic checkpoint control can then lead to
permanent incorporation of these genome abnormalities.
AR signaling is critical not only for normal development
of the prostate gland but also for prostate carcinogenesis.
Genomic instability is related to AR transcriptional activity,
and the cross-regulation between AR signaling and DNA
damage response pathways appears to be relevant for PC
progression [18]. Nevertheless, the role of AR in genome
instability is only partly understood [19,20].
Rearrangements between the androgen-regulated
TMPRSS2 gene and the ETS genes ERG, ETV1, and ETV4 are
common in PC; these appear to be early events contributing
to, but not sufficient on their own, prostate carcinogenesis,
and are at least partly lineage-specific [5]. AR-driven
transcription can result in increased DNA DSB generation
at transcriptional hubs, probably as a result of topoisomer-
ase-IIb enzyme activity, leading to complex structural
rearrangements across the genome [21,22]. Mechanistically,
this is supported by AR binding to specific chromosomal
sites creating a proximity to otherwise distant chromatin
loci [20]. TMPRSS2-ERG translocation is probably the
commonest example of such processes [23,24].
Interestingly, some PCs are characterized by high
numbers of rearrangements. Many of these tumors havetate Cancer: Biology and Clinical Implications. Eur Urol (2016),
Fig. 1 – An overview of the most important DNA damage–inducing stresses and the corresponding molecular pathways that eukaryotic cells established
to repair these. Diverse environmental and endogenous stresses can damage DNA, causing either single-strand (lilac) or double-strand (red box) DNA
breaks. Eukaryotic cells developed various molecular mechanisms that repair such damage. DNA double-strand breaks are the most toxic DNA
damage, and can be lethal for a cell if not properly repaired. The two most common and best-studied DNA double-strand repair pathways are
homologous recombination (HR; error-free) and nonhomologous end-joining (NHEJ; error-prone). HR is limited to the S/G2 phases of the cell cycle and
requires a sister chromatid as repair template. Key pathway components are highlighted. NHEJ is active mostly during the G1 phase of the cell cycle
and can lead to structural genomic alterations (rearrangements), loss of genomic material (deletion), or insertion of additional nucleotides as a
consequence of its imprecise nature. Key pathway components are highlighted.
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proteins including AR and its transcriptional regulators.
Mechanistically, SPOP mutant tumors rely predominantly
on NHEJ-based DSB repair (while reducing error-free HR-
mediated DSB repair activity) [25].
The pattern of genomic aberrations may partly depend
on deficiencies in specific DNA repair pathway branches. It
has been shown that loss of MMR function induces a
hypermutated microsatellite unstable genotype [12]. So-
matic complex rearrangements in MSH2 and MSH6, as well
as somatic and germline truncating mutations in these twoPlease cite this article in press as: Mateo J, et al. DNA Repair in Pros
http://dx.doi.org/10.1016/j.eururo.2016.08.037genes, have been described as the most common mecha-
nism for MMR-deficient prostate tumors [26,27]. BRCA2-
deficient PCs also present specific mutation signatures
enriched in deletions and with higher mutational burden
than wild-type–BRCA2 tumors [28,29].
3.4. Inherited mutations in DNA repair genes and PC risk
Hereditary germline mutations in DNA repair genes are
associated with a higher risk of PC. This results in one gene
allele being dysfunctional in every cell, with the secondtate Cancer: Biology and Clinical Implications. Eur Urol (2016),
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epigenetic silencing) [30]. Germline mutations in BRCA2
increase the risk of developing PC (relative risk 8.6 in
men <65 yr) [31,32]; their role in the development and
progression of breast, ovarian, and pancreatic cancers is also
well established. Moreover, inherited mutations in other
DNA repair genes such as PALB2, MLH1, MSH2, and PMS2
also appear to be associated with PC risk [33]. While the
proportion of patients carrying a germline BRCA1/2 muta-
tion is low (1–2%) among the general population of primary
PC patients, a multicenter study lead by the SU2C-PCF
consortium in metastatic PC patients estimated the preva-
lence of germline BRCA2 mutations as 5.3% in the setting of
advanced disease; when a panel of 20 DNA repair genes was
considered, 82/692 (11.8%) of patients with metastatic
disease carried an underlying germline mutation [34]. In-
terestingly, age at diagnosis and family history of PC did not
identify the mutation carriers, although there was enrich-
ment among patients with a family history of cancer. It is
therefore now critical to reconsider current guidelines for
germline DNA testing; this could be relevant not only for
treatment stratification but also in triggering cascade
genetic testing for relatives who may be candidates for
targeted cancer screening programs.
At present there is no consensus on how to manage this
high-risk population with regard to screening for PC. To
address this issue, the IMPACT study is evaluating targeted
PC screening in men with germline BRCA1/2 (gBRCA1/2)
mutations. Annual prostate-specific antigen (PSA) tests are
performed, and a biopsy is triggered if PSA >3ng/ml. A total
of 1522 gBRCA1/2 mutation carriers and 959 controls had
been recruited at last reporting. Preliminary results have
revealed a higher incidence of PC in gBRCA2 mutation carriers
(3.3% vs 2.6% in gBRCA1 mutation carriers, <2% for controls),
who also have a higher likelihood of intermediate/high risk.
Final results from these studies are awaited to ascertain the
optimal screening strategies for this population [35].
Inherited mutations impairing the MMR function (Lynch
syndrome) have been associated with an almost fivefold
higher risk of PC, although additional work is needed to
determine precise risks [36].
3.5. Impact of DNA repair defects on clinical outcome and
response to treatment in PC
The relevance of somatic loss of function of DNA repair
genes in the treatment of CRPC is still not clear, as neither
the TCGA (primary tumors) nor the SU2C/PCF (metastatic
disease) landscape studies reported follow-up clinical
outcome data. Prospective studies looking at whether this
molecular classification results in clinically relevant strati-
fication for prognosis and treatment response are needed
[8,12]. There are data on clinical outcome according to
gBRCA1/2 in localized disease. In a series of more than
2000 patients with localized PC, including 61 BRCA2 and 18
BRCA1 mutation carriers, 23% of gBRCA1/2 mutation carriers
developed metastasis after 5 yr of radical treatment,
compared to 7% of noncarriers (p = 0.001). Cause-specific
survival was significantly shorter among carriers (8.6 yr)Please cite this article in press as: Mateo J, et al. DNA Repair in Pros
http://dx.doi.org/10.1016/j.eururo.2016.08.037compared to noncarriers (15.7 yr; p = 9  108). Subgroup
analysis confirmed gBRCA2 mutations as independent factor
for poor prognosis [37]. The poorer outcome for gBRCA2
mutation carriers seems to be particularly relevant for
patients treated with radical radiotherapy in comparison to
surgery, although the patient numbers evaluated were too
small to support a robust claim [38]. The exact biological
reasons underlying this poorer outcome remain to be fully
elucidated; data from small series suggest that these tumors
remain sensitive to taxanes [39,40].
3.6. Using DNA repair defects as a therapeutic target:
PARP inhibitors
Over the last decade, exploitation of the vulnerabilities of
tumor cells with DNA repair gene defects has been pursued
in different tumor types, most successfully in ovarian and
breast cancers. The identification of a subgroup of mCRPC
with DNA repair defects with a similar genomic profile
provides a strong rationale for developing the same
therapeutic strategies for this molecular subtype of PC [10].
Poly (ADP-ribose) polymerases (PARP) are a family of
enzymes involved, primarily, in transcriptional regulation
and in detecting and localizing other DNA repair proteins to
DNA single strand breaks. Activation of PARP1 and PARP2
triggers the damage response and recruits of key effectors of
repair.
The fundamental basis for inhibiting PARP as anticancer
therapy is the established biological concept called syn-
thetic lethality: two genomic events that are each relatively
innocuous individually become lethal when occurring
together [41]. When PARP1/2 are pharmacologically inhib-
ited, SSBs cannot be repaired and eventually progress to
toxic DSBs. If a cell is competent in repairing damage, it will
be able to fix the DSB. However, if a cell is lacking HR repair
capacity (eg, BRCA1, BRCA2, PALB2 or ATM is dysfunctional or
lost), then PARP inhibiton would become lethal.
Two landmark studies demonstrated in 2005 specific
killing of cell lines in which BRCA1/2 had been silenced or
lost by the PARP inhibitor (PARPi) KU-0059436 (later named
AZD2281, olaparib) [42,43]. In these studies, PARP inhibition
led to gH2AX accumulation and the absence of RAD51 foci
formation in BRCA-deficient models. Subsequent studies
have revealed similar effects for other PARP inhibitors now
in clinical development, and demonstrated that sensitivity to
PARP inhibition also appears when other HR proteins besides
BRCA1/2 are nonfunctional or lost [44,45].
This mechanistic interpretation of PARPi-associated
synthetic lethality may, however, be a simplification of
the underlying biological effect. It is now clear that PARP1 is
involved in other DNA damage responses as well as SSBR,
with reported functions in DNA replication and repair of
stalled replication forks [46,47]. Moreover, certain PARP
inhibitors may also have a direct cytotoxic effect by
trapping PARP at DNA SSBs. These trapped PARP enzymes
eventually induce replication fork stalling, which results in
cell cycle arrest and apoptosis [48].
Lastly, of particular relevance to PC, PARP1 is involved in
transcriptional regulation and has been implicated in ARtate Cancer: Biology and Clinical Implications. Eur Urol (2016),
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between PARP1 and ERG, as well as an interaction between
PI3K/PTEN pathway aberrations and HR DNA repair [51,52],
also raised hopes for a wider target population. However,
these mechanisms have not been confirmed in human
clinical trials to date [53,54].
3.7. Clinical development of PARP inhibitors in PC
A first-in-man clinical trial of olaparib among a cohort of
patients with advanced solid tumors enriched in gBRCA1/2
mutation carriers provided critical proof of concept and
clinical data on the exquisite antitumor activity of this drug
in BRCA-deficient tumors [55]. Since then, olaparib has been
evaluated in several phase II/III studies, mainly in ovarian
cancer as a single agent, until granted US Food and Drug
Administration and European Medicines Agency approval
in 2014 for advanced ovarian cancer associated with BRCA1/
2 mutations [56–59].
With regard to mCRPC patients, a few carriers of
deleterious gBRCA1/2 mutations were enrolled in the initial
trials of olaparib, and showed promising tumor responses.
In a phase 2 basket trial including 298 gBRCA1/2 mutation
carriers with different tumor types, eight mCRPC patients
were enrolled (1 BRCA1 mutant carrier, 7 BRCA2 cases)
[60]. Half (4/8) of the mCRPC patients experienced a
radiologic partial response; the median progression-free
survival for all eight patients was 7.2 mo, with two patients
responding for over 1 yr. Of note, 4/8 patients had prior
treatment with platinum-based chemotherapy before
receiving olaparib. In line with data suggesting some
degree of secondary cross-resistance [61], only 1/4 patients
who were exposed to platinum responded to olaparib,
compared to 3/4 of those who were platinum-naı¨ve.
Other PARP inhibitors are in clinical development; data
for PC patients are primarily from gBRCA1/2 mutation
carriers with PC who participated in early clinical trials of
these compounds. Preclinical studies of BMN673 (Biomarin/
Medivation) demonstrated high potency in inhibiting PARP
[62], and tumor responses were seen in BRCA1/2 mutation
carriers across tumor types in a phase 1 clinical trial
[63]. Rucaparib (AG-014699/CO-338, Pfizer/Clovis Oncolo-
gy) and veliparib (ABT-888, Abbott Laboratories) have
mainly been developed so far in combination with
chemotherapies or other targeted agents [64,65].
The antitumor activity of PARP inhibitors as single agents
in patients besides gBRCA1/2 mutation carriers has been
investigated in two studies. During the first-in-man trial of
niraparib (MK-4827, Merck/Tesaro), an expansion cohort
for ‘‘sporadic’’ CRPC patients was pursued. Eighteen patients
received niraparib at the recommended phase 2 dose
(300 mg QD). One patient achieved a >50% decrease in PSA,
remaining on treatment for 10 mo [54]. Three more patients
had significant declines in circulating tumor cell (CTC)
counts for >6 mo. The trial was unable to associate
responses with either PTEN or ERG expression.
More recently, results from the first stage of a phase
2 investigator-initiated adaptive study of olaparib in mCRPC
have been reported, raising interest in developing PARPPlease cite this article in press as: Mateo J, et al. DNA Repair in Pros
http://dx.doi.org/10.1016/j.eururo.2016.08.037inhibitors for this disease. The TOPARP study conducted in
the UK included a first stage (TOPARP-A) aimed at testing
the antitumor activity of olaparib in a ‘‘sporadic’’ mCRPC
population (not known to be gBRCA1/2 mutation carriers
and not selected based on any prior knowledge of the
genomic background) [66]. The primary endpoint of the
study was the response rate, using a composite definition of
response: radiologic response according to RECIST 1.1 and/
or PSA declines >50% and/or conversion in CTC count from
poor (>5 CTC/7.5 ml of blood) to positive prognostic profile
(5 CTC/7.5 ml of blood), confirmed in at least two readings
4 wk apart. Progression-free and overall survival were
explored as secondary endpoints. Response to olaparib was
evaluated in 49/50 patients who received at least one dose
of olaparib. These were all mCRPC patients progressing on
docetaxel and, for all but one, on abiraterone and/or
enzalutamide. Some 58% of patients also progressed on
cabazitaxel before participating in the study. Of the
49 patients, 16 fulfilled at least one of the response criteria,
including 11 cases with a PSA decline >50% and 6/32 with
radiologic partial responses among the patients with
measurable disease. The antitumor activity observed was
strongly associated with the presence of mutations or
homozygous deletions in DNA repair genes, evaluated by
next-generation sequencing for metastatic biopsies collect-
ed at trial entry. Seven patients were found to have biallelic
loss of BRCA2, either by germline or somatic mutations and
deletions, with all seven responding to therapy. In five
cases, mutations impacting ATM function were found; 4/5
responded to olaparib, including patients with germline and
somatic mutations, and two patients with a single-allele
mutation in the ATM kinase domain and no evidence of
biallelic loss. Moreover, four cases with biallelic events in
other genes involved in DNA damage response, including
PALB2, FANCA, and BRCA1, showed benefit, primarily
involving prolonged CTC conversions. Only two patients
responding to olaparib did not have a clear DNA repair
defect according to genomic analysis. Several long response
durations were observed, including four patients benefiting
for >1 yr. Patients with defects in DNA repair genes
exhibited improved progression-free and overall survival
from treatment initiation, although the preliminary survival
data reported will need to be re-evaluated after longer
follow-up.
The promising results in this first stage of the TOPARP
study led to initiation of a second trial (TOPARP-B) with
prospective selection of patients with aberrations in DNA
repair genes; the objectives are to validate the antitumor
activity seen in patients with the most common mutations
(BRCA2, ATM) and to acquire critical data on sensitivity to
olaparib for patients with mutations or deletions in less
commonly affected genes.
The tolerability profile of PARP inhibitors is manageable,
with anemia, thrombocytopenia, fatigue, and gastrointesti-
nal toxicities (primarily nausea) the most frequent. In the
TOPARP-A trial, anemia (20%) and fatigue (12%) were the
most common grade 3 adverse events; gastrointestinal
toxicities were less relevant than reported for ovarian
cancer [67]. Hematologic toxicities and fatigue were alsotate Cancer: Biology and Clinical Implications. Eur Urol (2016),
E U R O P E A N U R O L O G Y X X X ( 2 0 1 6 ) X X X – X X X 7
EURURO-6992; No. of Pages 9the dose-limiting events determining the recommended
dose for other PARP inhibitors such as BMN673 and
niraparib [54,63].
PARP inhibitors are also being evaluated in combination
trials in mCRPC. An obvious strategy is to combine PARPi
with DNA-damaging agents, mostly chemotherapy agents,
to achieve a synergistic effect by blocking the response to
chemotherapy-induced DNA damage. In a trial of veliparib
and the alkylating agent temozolamide [65], 2/26 treated
patients experienced PSA declines of >30%; the rate of grade
3–4 anemia and thrombocytopenia was 15% and 23%
respectively. Overlapping hematologic toxicities also rep-
resent a major hurdle for combining platinum chemothera-
pies and PARPi.
An alternative approach would be to aim for a synthetic
lethal interaction rather than a synergistic effect. Preclinical
data demonstrating enhanced death of prostate tumor cells
when combining HDAC and PARPi exemplify an opportuni-
ty for clinical development [68].
Lastly, trials combining PARPi with AR-targeting agents
may be of interest on the basis of the crossregulation of both
pathways and the central role of hormonal therapy in PC.
Preliminary results from a randomized trial combining
veliparib and abiraterone determined that 27% of patients
had aberrations in DNA repair genes; this subgroup
experienced high response rates to the combination and,
remarkably, to abiraterone alone [53]. Data from a
randomized trial combining abiraterone and olaparib are
also expected. However, interpretation of putative predic-
tive biomarkers of response in combination trials may be
challenging.
3.8. DNA damaging agents: should they be reconsidered for PC?
Platinum salts are part of standard management for other
tumor types, but their use in PC has been limited since
phase 3 trials of the orally available platinum derivative
satraplatin failed to meet the primary endpoint of overall
survival (OS) improvement [69]. However, some antitumor
activity has been described for carboplatin, cisplatin, and
satraplatin in mCRPC. This, together with the possibility
now of identifying DNA repair–defective tumors and data
on DNA repair mutations and response to platinum from
ovarian cancer studies, has raised interest in re-evaluating
the role of platinum agents in this disease.
Recently, Kumar et al reported longer benefit from
carboplatin for cases with HR defects in a retrospective
series of patients (p = 0.002 for duration of treatment,
n = 21). Small case series have reported tumor responses to
carboplatin in mCRPC patients with biallelic BRCA2 loss
[70]. Nonetheless, the mechanisms involved in sensitivity to
platinum and PARPi may be similar but not identical, and
further investigation of cross-sensitivity and cross-
resistance between agents is now needed following data
from ovarian cancer studies. For example, the predomi-
nance of NER in repairing platinum-generated adducts
warrants specific clinical trials [71,72].
A few clinical trials have explored combinations of
carboplatin and taxanes for PC. One of the most relevantPlease cite this article in press as: Mateo J, et al. DNA Repair in Pros
http://dx.doi.org/10.1016/j.eururo.2016.08.037was a phase 2 study of carboplatin and docetaxel, followed
by cisplatin and etoposide on progression. The study
recruited 120 patients with mCRPC with prespecified
clinicopathologic characteristics suggestive of more aggres-
sive, arguably less AR-dependent disease [73]. With median
OS of 16 mo, the radiological response rate was 30% for
both first- and second-line combinations. The tolerability
was relatively acceptable, with only three cases of febrile
neutropenia.
Use of the topoisomerase inhibitor mitoxantrone in PC
has declined as several other therapies became available
over the last decade. However, the main mechanism in the
cytotoxicity of mitoxantrone is disruption of DNA synthesis
and repair, so re-evaluation of its activity in molecularly
defined populations may be of interest.
4. Conclusions
The identification of a subgroup of PCs with lethal disease
with genomic deleterious aberrations of DNA repair genes
supports further evaluation of this biomarker-driven
treatment stratification of advanced PC in registration
studies. If the efficacy of this strategy is, it might also be
possible to apply it to earlier disease stages, including high-
risk locally advanced disease.
Further studies are now needed to clinically qualify
multiplex predictive biomarkers of DNA repair–defective
PCs, particularly for the less common genomic aberrations
that cause this phenotype. On the basis of recent studies
indicating that these aberrations are common in the
germline DNA of patients with metastatic PC, somatic
and germline DNA testing for patients with advanced PC
should be considered in view not only of the therapeutic
consequences for the patient but also the possibility of
pursuing targeted screening in this population. A major
limitation at present for adoption of this strategy is the
implementation and standardization of genomic testing in
the community setting, but the decreasing costs of next-
generation sequencing and lessons learned from stratified
therapies in other diseases will help us to pursue more
precise care for PC patients.
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